ArticlePloS one2015

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.

Wolf Peter Hofmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.